340B claims data submission is the process of taking a dispensed prescription, generating a data file through a third-party administrator (TPA), and uploading it to a manufacturer portal within a fixed window, usually 45 days, to keep the 340B price on that claim. For a well-staffed hospital system, that process runs in the background. For […]
340B Claims Data Submission: What It Actually Costs an FQHC Pharmacy Read More »
HRSA audit readiness is the ability to explain, with evidence, why a 340B program operated the way it did on an ordinary day, not just the ability to assemble a binder quickly after an audit letter arrives. That distinction sits at the center of a recent episode of 340B Pulse, the NorthArc Health podcast powered
HRSA Audit Readiness: What 10 Real Audits Taught One 340B Program Read More »
Most 340B programs can produce a binder in three weeks. Very few can explain what their controls were doing in the eleven months before the letter arrived. That gap is the whole subject of this article, and it is where 340B audit readiness either exists or does not. Everything below is drawn from an operator
340B Audit Readiness: The 7 Controls That Hold When Nobody Is Watching Read More »
Strong 340B operations are a set of small, repeatable habits: running the reports that show where prescriptions actually go, reviewing what failed to capture, checking wholesaler invoices against the 340B price, and owning the program rather than delegating it to software. Programs that build these habits absorb pricing and regulatory pressure. Programs that skip them
340B Operations: The 7 Habits That Protect a Program Before Anything Goes Wrong Read More »
340B rebate readiness is the operational capacity to identify, validate, submit, and reconcile claims under a rebate-based 340B model, then confirm that the rebate actually received matches what was owed. It is not the act of uploading a file once a month. Done correctly, it is a continuous cycle of data cleanup, exception handling, and
340B Rebate Readiness: Why the Five-Hour Myth Is Actually an Iceberg Read More »
340B mission impact is the outcome that results when a covered entity’s leadership makes intentional, defensible, and well-governed decisions about how to allocate 340B savings across competing needs. It is not automatic. Savings only become mission impact when leaders choose where the money goes and can prove why. That distinction sits at the center of
340B Mission Impact: How One Rural Health Center Turns Savings Into Real Patient Care Read More »
The orphan drug blind spot in 340B refers to the missed financial savings, often ranging from $200,000 to $450,000 annually, by rural and expansion hospitals that fail to capture discretionary pricing on orphan medications. Because of complex exclusions established under the Affordable Care Act, many hospital pharmacy teams mistakenly believe these high-cost specialty drugs are
What Is the Orphan Drug Blind Spot in 340B and How Can Hospitals Find Missing Savings? Read More »
